Please login to the form below
inflammatory diseases
This page shows the latest inflammatory diseases news and features for those working in and with pharma, biotech and healthcare.
Lilly signs $960m deal with Rigel to develop RIPK1 inhibitors
Lilly will co-develop and commercialise R552 across all indications, including autoimmune and inflammatory diseases. ... The ethos behind RIPK1 inhibitor development is to offer a new kind of approach towards treating a range of autoimmune, inflammatory
Latest news
-
Horizon bolsters rare disease portfolio with $3bn Viela Bio acquisition
Viela is also evaluating Uplizna in phase 3 trails in the rare autoimmune neuromuscular disorder myasthenia gravis and in IgG4-related diseases. ... We believe that the combined pipeline, including the pursuit of additional potential indications, has the
-
Sanofi gains access to antibody tech with Kymab acquisition
treat a range of immune-mediated disorders and inflammatory diseases. ... The Kymab acquisition adds KY1005 to our dynamic pipeline, a potential first-in-class treatment for a range of immune and inflammatory diseases.
-
Novartis’ canakinumab failed to improve survival in COVID-19 study
Excessive production of IL-1β plays a significant role in certain inflammatory diseases and immune responses. ... Developers theorised that these drugs could have an impact on CRS, a form of systemic inflammatory response that can occur as a
-
Lilly cuts deal with UK’s Sitryx for autoimmune disease drugs
The five-year deal includes Sitryx’ two lead projects, although there’s little information available yet on the diseases targeted by those programmes as they are still in the discovery phase. ... The partnership complements Lilly’s existing focus
-
Bayer signs €250m pact with India’s Curadev for STING drugs
Research will focus on auto-immune and inflammatory diseases. The immune checkpoint STING has seen some popularity as a target for cancer drug development, but Bayer and India’s Curadev have ... started working on STING drugs with potential in
More from news
Approximately 4 fully matching, plus 130 partially matching documents found.
Latest Intelligence
-
Switzerland: a life sciences hub
oral treatments to treat patients with inflammatory bowel diseases. ... The company has been using artificial intelligence for the past eight years to help detect certain diseases such as cancer.
-
20 for 2020 – Five pharma leaders to watch in 2020
In the meantime, Sanofi is stepping up its focus in other areas like immunological and inflammatory diseases, rare blood disorders and vaccines, as well as cancer – an area it had been ... Meanwhile, Galapagos looks set to continue adding to its
-
Innovation in merger control and the impact on the pharmaceutical sector
Specifically, Hospira was selling Inflectra, an infliximab biosimilar used to treat several chronic inflammatory diseases, notably the inflammation of Crohn’s disease, while Pfizer was in an advanced stage of developing
-
‘How is your day?’
Physicians need to be more aware of rare diseases that may hide behind recurring issues that some patients have. ... These are: Primary Immunodeficiency Diseases (PID – causes severe infections); Chronic Inflammatory Demyelinating Polyneuropathy (CIDP
-
The tipping point
In chronic diseases such as rheumatoid arthritis and inflammatory bowel disease, there are significantly greater savings from switching patients compared with initiating biosimilars in naïve patients alone.
More from intelligence
Approximately 0 fully matching, plus 13 partially matching documents found.
Latest appointments
-
Dr Kunwar Shailubhai appointed CEO of Tiziana Life Sciences
He has 30 years’ experience in research and development specifically in gastrointestinal disorders, inflammatory diseases and cancers, and previously co-founded Synergy Pharmaceuticals and served as its chief scientific officer.
-
Kymab appoints its first chief medical officer
She has over 20 years of experience biomedical research and has focused on pathogenic mechanisms, underlying chronic inflammatory diseases and the interface between autoimmunity and cancer.
-
Dr Li Zhou joins TxCell as cell engineering VP
Dr Zhou will lead the team's discovery and engineering activities on Chimeric Antigen Receptor in Treg cells ( CAR-Treg) for immunotherapy of severe chronic autoimmune and inflammatory diseases and organ
-
Vedanta Biosciences appoints two new heads
Vedanta is advancing a pipeline of product candidates designed to treat autoimmune, inflammatory and infectious diseases using technology that mines the human microbiome for potent pharmaceutical products.
-
Lorin Johnson joins Atlantic Healthcare board
Atlantic's lead asset, alicaforsen for the treatment of the inflammatory bowel diseases ulcerative colitis and pouchitis.
More from appointments
Approximately 0 fully matching, plus 12 partially matching documents found.
Latest from PMHub
-
Infographic: Spondyloarthritis
Overview of spondyloarthritis patient profiles and treatment pathways. Spondyloarthritis is the name for a family of arthritis causing inflammatory rheumatic diseases; including axial spondyloarthritis, psoriatic arthritis and akylosing spondylitis,
More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
- Sales Director, Healthcare communications agency, London/ SE UK
-
Six figure salary
- Senior Account Director - Med Comms Agency
-
Salary TBC
- ACCOUNT MANAGER / SENIOR ACCOUNT MANAGER
-
Salary TBC
-
SENIOR MEDICAL WRITER
-
Salary TBC
-
MEDICAL WRITER - HOME WORKING
-
Salary TBC
- Bayer’s finerenone scores FDA priority review for chronic kidney disease
- GSK launches late-stage testing of RSV vaccine candidate in older adults
- Pfizer/BioNTech to develop a booster dose for their COVID-19 vaccine
- Sinovac’s COVID-19 vaccine appears safe in older adults
- bluebird bio posts modest Q4 revenue growth as it continues investigation into troubled LentiGlobin
- FDA schedules meeting on 26 February to review J&J’s one-dose COVID-19 vaccine
- FDA authorises flexible storage for Pfizer/BioNTech COVID-19 vaccine
- UK introduces Rare Diseases Framework to improve the lives of people with rare diseases
- Protalix, Chiesi’s monthly treatment PRX-102 shows benefit in Fabry disease
- UPDATED: Regeneron’s COVID-19 antibody cocktail shows ‘clear efficacy’
- Merck to acquire Pandion Therapeutics for $1.85bn
- bluebird bio marks Rare Disease Day 2021 with launch of patient testimonial video
PMHub
OPEN Health
OPEN Health is a family of expert practices, working in partnership to drive positive change in healthcare communications & market...
Latest intelligence
- 4 ways to recruit Alzheimer’s disease patients for your clinical trial
- What key things do you need to remember to reach patients living with Alzheimer’s disease?...
- Integrating competitive intelligence into business development, licensing and M&A strategy
- The advantages of partnering with a competitive intelligence or knowledge management team...
- Reaching patients and HCPs during the pandemic
- COVID-19 has caused unprecedented disruption to drug launches, but some pharma companies avoided costly delays by quickly pivoting to digital channels...
Quick links
Infographics
